| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Financial Officer | CFO &Vp-business Development +1 more
3 companies
Van Voorhees Seth serves as a CFO &Vp-business Development at REFR and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 6 buys and 0 sells. Those positions are worth an estimated $918K at current prices.
Historically, Van Voorhees Seth's trades have earned a below-average insider score of 21/100 across 3 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -69.4%.
The biggest single holding is REFR (~$717K) as CFO &Vp-business Development. Net of sales, the recent Form 4 record there shows accumulation of 4,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2022 | NRXP Nrx Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 30,000 | $1.10 | $33,000.00 | +183.6% | -40.2% | -70.5% | |
| Nov 25, 2022 | NRXP Nrx Pharmaceuticals, Inc. | Chief Financial Officer | Buy | 16,337 | $1.11 | $18,215.23 | +40,843% | -9.6% | -72.7% | |
| Jun 15, 2021 | PDSB Pds Biotechnology Corp | Chief Financial Officer | Buy | 17,647 | $8.50 | $149,999.50 | New | +62.9% | -64.9% | |
| Sep 12, 2017 | REFR Research Frontiers Inc | CFO &Vp-buisness Develpoment | Buy | 4,000 | $1.15 | $4,600.00 | +3.0% | - | - |